Detalhe da pesquisa
1.
Discovery of GNE-502 as an orally bioavailable and potent degrader for estrogen receptor positive breast cancer.
Bioorg Med Chem Lett
; 50: 128335, 2021 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34425201
2.
Discovery of a C-8 hydroxychromene as a potent degrader of estrogen receptor alpha with improved rat oral exposure over GDC-0927.
Bioorg Med Chem Lett
; 29(16): 2090-2093, 2019 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31311734
3.
GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer.
J Med Chem
; 64(16): 11841-11856, 2021 08 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-34251202
4.
Discovery of GNE-149 as a Full Antagonist and Efficient Degrader of Estrogen Receptor alpha for ER+ Breast Cancer.
ACS Med Chem Lett
; 11(6): 1342-1347, 2020 Jun 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32551022
5.
Identification and optimisation of a series of substituted 5-(1H-pyrazol-3-yl)-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
Bioorg Med Chem Lett
; 17(2): 370-5, 2007 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-17095213
6.
Identification and optimisation of a series of substituted 5-pyridin-2-yl-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
Bioorg Med Chem Lett
; 17(2): 363-9, 2007 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-17107790
7.
D-myo-inositol-1,4,5-trisphosphate and adenophostin mimics: importance of the spatial orientation of a phosphate group on the biological activity.
Bioorg Med Chem
; 10(3): 759-68, 2002 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-11814866